Form 8-K - Current report:
SEC Accession No. 0001213900-24-096799
Filing Date
2024-11-12
Accepted
2024-11-12 16:12:54
Documents
15
Period of Report
2024-11-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0220665-8k_longe.htm   iXBRL 8-K 26273
2 PRESS RELEASE ISSUED BY THE COMPANY ON NOVEMBER 12, 2024 ea022066501ex99-1_longe.htm EX-99.1 90563
3 GRAPHIC ex99-1_001.jpg GRAPHIC 9137
  Complete submission text file 0001213900-24-096799.txt   319501

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE lgvn-20241112.xsd EX-101.SCH 3021
5 XBRL LABEL FILE lgvn-20241112_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE lgvn-20241112_pre.xml EX-101.PRE 22363
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0220665-8k_longe_htm.xml XML 3799
Mailing Address 1951 NW 7TH AVENUE SUITE 520 MIAMI FL 33136
Business Address 1951 NW 7TH AVENUE SUITE 520 MIAMI FL 33136 305-302-7158
Longeveron Inc. (Filer) CIK: 0001721484 (see all company filings)

EIN.: 472174146 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40060 | Film No.: 241448283
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)